Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood (2023) 142 (Supplement 1): 4458.

https://doi.org/10.1182/blood-2023-181385

Published: 2023

Journal Articles

KMT2D Deficiency Promotes Myeloid Leukemias through Regulating Ribosome Biogenesis

Jing Xu, Ailing Zhong, Chong Chen, Yu Liu, Ting Niu

Blood (2022) 140 (Supplement 1): 5855–5856.

https://doi.org/10.1182/blood-2022-168509

Published: 2022

Journal Articles

Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma

Alejandro Berkovits, Eduardo Yanez, Christine Rojas, Raimundo Gazitua, Nicolás Cazap, Anna Sureda, Rao Saleem, Robin Meng, Jing Xu, Michael Streit, Valentine Barboux, Sairah Ahmed

Blood (2022) 140 (Supplement 1): 12020–12021.

https://doi.org/10.1182/blood-2022-159980

Published: 2022

Journal Articles

Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34 + Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Blood (2022) 140 (Supplement 1): 10652–10653.

https://doi.org/10.1182/blood-2022-166365

Published: 2022

Journal Articles

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

Stephan M Tirier, PhD, Jan-Philipp Mallm, PhD, Nicola Casiraghi, PhD, Hana Susak, PhD, Nicola Giesen, MD, Alexandra M Poos, PhD, Katharina Bauer, Anja Baumann, Lukas John, MD, Jing Xu, PhD, Lara Klett, MSc, Carsten Müller-Tidow, MD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Niels Weinhold, PhD, Oliver Stegle, PhD, Karsten Rippe, PhD, Marc S. Raab, MD

Blood (2019) 134 (Supplement_1): 571.

https://doi.org/10.1182/blood-2019-128625

Published: 2019

Journal Articles

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 575.

https://doi.org/10.1182/blood-2019-130051

Published: 2019

Journal Articles

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Niels Weinhold, PhD, Jing Xu, PhD, Martina Fröhlich, PhD, Alexandra M Poos, PhD, Lukas John, MD, Carsten Müller-Tidow, MD, Sandra Sauer, MD, Stefanie Huhn, PhD, Dirk Hose, MD, Anja Seckinger, Kari Hemminki, MD PhD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Nicola Giesen, MD, Marc S Raab, MD PhD

Blood (2019) 134 (Supplement_1): 1783.

https://doi.org/10.1182/blood-2019-131195

Published: 2019

Journal Articles

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Jing Xu, Qisu Zhang, MPH, Mehul Dalal, PhD

Blood (2019) 134 (Supplement_1): 4751.

https://doi.org/10.1182/blood-2019-129053

Published: 2019

Journal Articles

mTOR Signal Pathway Inhibition Promote the Cytotoxicity of Chemotherapy on SHI-1 Cells

Jing Xu, Zhenjiang Li, Jifu Zheng, Qiong Wu, Qingming Wang, Aiping Tang, Yuan Song, Yan Fei

Blood (2019) 134 (Supplement_1): 5126.

https://doi.org/10.1182/blood-2019-126714

Published: 2019

Journal Articles

Spectrum of Gene Mutations and Clinical Significance in Myeloid Malignancies Patients with ASXL1 Mutations

Jie Bai, MD, Guangshuai Teng, Yingshao Wang, Jing Xu, Chenxiao Du, Yan Wang, Yafang Chen, Mengyao Sheng, PhD, Jiaojiao Bai, Lei Zhang, MD, Yuan Zhou, PhD, Feng-Chun Yang, MD PhD

Blood (2018) 132 (Supplement 1): 3906.

https://doi.org/10.1182/blood-2018-99-114471

Published: 2018

Journal Articles

Rapamycin Promote the Inhibition Rate of Proliferation on SHI-1 Cells and Enhance the Efficacy of Chemotherapy in Npg Leukemia Mice

Jing Xu, Zhenjiang Li, Jifu Zheng, Qiong Wu, Qingming Wang, Aiping Tang, Yuan Song, Yan Fei

Blood (2018) 132 (Supplement 1): 5217.

https://doi.org/10.1182/blood-2018-99-112877

Published: 2018

Journal Articles

Establishment of Human Acute Monocyte Leukemia Model with Systemic Leukemia in Npg Mice

Jing Xu, Zhenjiang Li, Qiong Wu, Wenfeng He, Jifu Zheng, Qingming Wang, Aiping Tang, Wanlei Sun, Yanfei Rao

Blood (2018) 132 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2018-99-112395

Published: 2018

Journal Articles

KMT2D Is a Haploinsufficient Tumor Suppressor in Acute Leukemia

Jing Xu, MD, Yu Liu, PhD, Chong Chen, PhD, Ting Niu, MD PhD

Blood (2018) 132 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2018-99-119038

Published: 2018

Journal Articles

Profiling of Oncogenic Signaling in Multiple Myeloma — Association with Biology, Disease Progression and Prognosis

Nicola Lehners, Jing Xu, Thomas Hielscher, Leo Rasche, Elena Ellert, Albrecht Stenzinger, Peter Schirmacher, Carsten Müller-Tidow, MD, Hartmut Goldschmidt, MD, Mindaugas Andrulis, Niels Weinhold, PhD, Marc S Raab, MD

Blood (2018) 132 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2018-99-116214

Published: 2018

Journal Articles

Primary cutaneous small/medium CD4 + T-cell lymphoproliferative disorder

Jing Xu, Qin Huang

Blood (2018) 132 (7): 765.

https://doi.org/10.1182/blood-2018-05-850941

Published: 2018

Journal Articles

Comprehensive Genomic Characterization of Refractory Multiple Myeloma Reveals a Complex Mutational and Structural Landscape Associated with Drug Resistance

Nicola Lehners, MD, Umut H Toprak, Jing Xu, Nagarajan Paramasivam, Daniel Hübschmann, Martina Fröhlich, Nur H Md Hanafiah, Sadaf Mughal, Elias K Mai, MD, Anna Jauch, Jens Hillengass, MD, Roland Eils, Carsten Müller-Tidow, Benedikt Brors, Hartmut Goldschmidt, MD, Matthias Schlesner, Marc S Raab, MD PhD

Blood (2017) 130 (Supplement 1): 266.

https://doi.org/10.1182/blood.V130.Suppl_1.266.266

Published: 2017

Journal Articles

Sequential Cellular Niche Plays a Crucial Role in the Generation of Enucleated Erythrocytes from Human Pluripotent Stem Cells

Jun Shen, Ziceng Feng, Cuicui Lyu, Dixie Hoyle, Guangzhen Ji, Wei Wen, Jing Xu, Lu Zhang, Jianping Zhang, Xiaobing Zhang, Tao Cheng, MD, Zack Wang, PhD

Blood (2017) 130 (Supplement 1): 1159.

https://doi.org/10.1182/blood.V130.Suppl_1.1159.1159

Published: 2017

Journal Articles

Oncogene Induced Senescence As a Potential Breakpoint Mechanism Against Malignant Transformation in Plasma Cell Disorders

Nicola Lehners, MD, Elena Ellert, MD, Jing Xu, Hartmut Goldschmidt, MD, Mindaugas Andrulis, MD, Marc S. Raab, MD

Blood (2016) 128 (22): 4474.

https://doi.org/10.1182/blood.V128.22.4474.4474

Published: 2016

Journal Articles

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

K. Martin Kortüm, Elias K. Mai, Nur H. Hanafiah, Chang-Xi Shi, Yuan-Xiao Zhu, Laura Bruins, Santiago Barrio, Patrick Jedlowski, Maximilian Merz, Jing Xu, Robert A. Stewart, Mindaugas Andrulis, Anna Jauch, Jens Hillengass, Hartmut Goldschmidt, P. Leif Bergsagel, Esteban Braggio, A. Keith Stewart, Marc S. Raab

Blood (2016) 128 (9): 1226–1233.

https://doi.org/10.1182/blood-2016-02-698092

Published: 2016

Includes: Supplemental data

Journal Articles

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

Marc S. Raab, Nicola Lehners, Jing Xu, Anthony D. Ho, Peter Schirmacher, Hartmut Goldschmidt, Mindaugas Andrulis

Blood (2016) 127 (17): 2155–2157.

https://doi.org/10.1182/blood-2015-12-686782

Published: 2016

Includes: Supplemental data

NARROW

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

KMT2D Deficiency Promotes Myeloid Leukemias through Regulating Ribosome Biogenesis

Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma

Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34 + Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

mTOR Signal Pathway Inhibition Promote the Cytotoxicity of Chemotherapy on SHI-1 Cells

Spectrum of Gene Mutations and Clinical Significance in Myeloid Malignancies Patients with ASXL1 Mutations

Rapamycin Promote the Inhibition Rate of Proliferation on SHI-1 Cells and Enhance the Efficacy of Chemotherapy in Npg Leukemia Mice

Establishment of Human Acute Monocyte Leukemia Model with Systemic Leukemia in Npg Mice

KMT2D Is a Haploinsufficient Tumor Suppressor in Acute Leukemia

Profiling of Oncogenic Signaling in Multiple Myeloma — Association with Biology, Disease Progression and Prognosis

Primary cutaneous small/medium CD4 + T-cell lymphoproliferative disorder

Comprehensive Genomic Characterization of Refractory Multiple Myeloma Reveals a Complex Mutational and Structural Landscape Associated with Drug Resistance

Sequential Cellular Niche Plays a Crucial Role in the Generation of Enucleated Erythrocytes from Human Pluripotent Stem Cells

Oncogene Induced Senescence As a Potential Breakpoint Mechanism Against Malignant Transformation in Plasma Cell Disorders

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only